Where does Sirna Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Sirna Therapeutics, Inc. ranks #4,843 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Sirna Therapeutics, Inc. hold?

Sirna Therapeutics, Inc. holds 72 US utility patents granted between 2015 and 2025, spanning 11 technology areas.

What is Sirna Therapeutics, Inc.'s Innovation Score?

Sirna Therapeutics, Inc. has an Innovation Score of 39.9 out of 100 (top 37% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Sirna Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Sirna Therapeutics, Inc.'s recent grant velocity is -66% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Sirna Therapeutics, Inc.'s patents?

Sirna Therapeutics, Inc.'s patents average 19.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Sirna Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Sirna Therapeutics, Inc.

Q: What technology areas does Sirna Therapeutics, Inc. focus on?

Sirna Therapeutics, Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 70 patents. Grants appear in 11 CPC subclasses total.

USPTO PatentsView assignee record - 72 granted patents across 11 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Sirna ranks #4,843 of 49,997 tracked US assignees by granted-patent volume, with 72 patents across 11 technology areas.

#4,843
of 49,997 US assignees by volume: Top 37%
by Innovation Score (39.9/100): 19.4
avg claims per patent: -66%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4843 · US Corporation #4,843 · 72 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 72 grants
TOP-DECILE #4,843/49,997
PHOTO-FINISH Saluda Medical Pty
CPC-FOCUS C12N · 11 areas
INNOV-THIN 39.9/100
CLAIMS-RICH 19.4 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -66% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Saluda Medical Pty Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Sirna Therapeutics · this assignee

40
Topera · near

40
Twistlock · near

40
Venus Medtech… · near

40
Wyse Technology L L C · near

40
3D Lighting… · lowest

7

What this shows Sirna's Innovation Score is 39.9/100 (top 37% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Sirna's grants concentrate

Sirna Therapeutics, Inc. is a focused PatentsView assignee: 11 CPC subclasses with 97.2% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2017 (16 grants) versus a trough of 2 in 2022. By volume, Sirna sits between Shire Human Genetic Therapies, Inc. and Tianjin Wanda Tyre Co., Ltd..

Sirna's three-year grant acceleration

From 2019–2021 to 2022–2024, Sirna Therapeutics, Inc. moved from 20 to 5 grants (0.25x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Shire Human Genet…

72
Shoei Chemical

72
SK Hynix Nand Pro…

72
Saluda Medical Pty

72
Sococo

72
Texas Instruments…

72
THE University OF…

72
Tianjin Wanda Tyre

72
Sirna Therapeutics ◀

72

What this shows Sirna holds 72 patents at rank #4,843, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sirna

By rank, the assignees closest to #4,843 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Sirna's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Sirna, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (40 here).

Venus Medtech (HANGZHOU), Inc. 40 Wyse Technology L.L.C. 40 Topera Inc. 40 Twistlock Ltd. 40

Similar claim depth

Nearest assignees by average claims per patent (19.4 here).

Innovex Downhole Solutions, Inc. 19.4 avg FloDesign Sonics, Inc. 19.4 avg University of Maine System Board of Trustees 19.4 avg rewardStyle, Inc. 19.4 avg

Sirna's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 37% higher than 63% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Sirna Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	9	12.5%
2016	12	16.7%
2017	16	22.2%
2018	9	12.5%
2019	7	9.7%
2020	10	13.9%
2021	3	4.2%
2022	2	2.8%
2024	3	4.2%
2025partial year	1	1.4%

Which technologies does Sirna Therapeutics, Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 70

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 43

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 29

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 26

C07C - Acyclic OR Carbocyclic Compounds 18

C07D - Heterocyclic Compounds 13

C12Y - Enzymes 11

Y10S - Technical Subjects Covered BY Former Uspc Cross-reference ART Collections [XRACs] AND Digests 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

C07J - Steroids 2

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 1

Top 11 of 11 technology areas

Where it ranks

Overall rank by patents

#4,843

of 49,997 tracked assignees

Innovation Score

39.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Sirna Therapeutics, Inc.'s patent record in context - here's where to go next.

Sirna Therapeutics, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 97.2% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #4,843 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Sirna Therapeutics, Inc. against Shire Human Genetic Therapies, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.